Quantcast

Latest HER2/neu Stories

2014-10-22 23:06:39

RnRMarketResearch.com adds “Perjeta & Kadcyla (HER2-Positive Breast Cancer) – Forecast and Market Analysis to 2023” to its store.

2014-10-22 08:30:21

DALLAS, October 22, 2014 /PRNewswire/ -- RnRMarketResearch.com adds PharmaPoint: HER2-Positive Breast Cancer - Drug Forecast and Market Analysis to 2023 research reports

2014-10-21 12:29:40

However, Restrictions in Drug Coverage and Molecular Testing Limit Patient Access to Biomarker-Associated Agents, According to Findings from Decision Resources Group BURLINGTON, Mass., Oct.

2014-09-29 16:23:53

In the news release, The Gastric Cancer Market is Expected to More Than Triple Over the Next Ten Years, Capturing Nearly $3.8 million by 2023, issued 18-Sep-2014 by Decision

roche
2014-09-29 05:16:14

Perjeta, a new breast cancer drug developed by Swiss pharmaceutical company Roche, has shown “unprecedented” success in extending the lives of patients in a clinical trial, according to research results released on Sunday.

2014-09-18 12:27:44

Several Emerging Therapies Will Expand Treatment Armamentarium for Unresectable Locally Advanced or Metastatic Gastric Cancer, According to Findings from Decision Resources Group BURLINGTON,

2014-09-10 23:04:55

MarketOptimizer.org adds “EpiCast Report: Breast Cancer (HER2-, HER2+) – Epidemiology Forecast to 2023” to its store. Dallas, Texas (PRWEB) September 10,

2014-09-09 08:31:36

Additional Data Acceptances Include Multiple Oncotype DX® Studies in Breast and Renal Cancers REDWOOD CITY, Calif., Sept. 9, 2014 /PRNewswire/ -- Genomic Health, Inc.


Word of the Day
deuteragonist
  • A person in a secondary role, specifically the second most important character (after the protagonist).
The word 'deuteragonist' comes from a Greek word meaning 'an actor of second-class parts'.
Related